lonafarnib has been researched along with Disease Models, Animal in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Cabral, WA; Collins, FS; Cubria, MB; DuBose, A; Erdos, MR; Kamalapathy, P; Karim, L; Masoudi, A; Nazarian, A; Oftadeh, R; Snyder, BD; Suarez, S | 1 |
| Bram, Y; Chiriboga, L; Cullen, J; Frankel, AS; Gerges, S; Giersch, K; Heller, B; Hrebikova, G; Huang, T; Johnson, H; Low, BE; Lutgehetmann, M; Nahass, RG; Pais, MA; Ploss, A; Schwartz, RE; Sellau, J; Seneca, K; Sharon, Y; Shirvani-Dastgerdi, E; Toettcher, JE; Wiles, MV; Winer, BY | 1 |
| Boctor, D; Cerovac, V; Cuervo, AM; Diaz, A; Fisher, SK; Giroux, M; Goate, AM; Guzman, E; Haggarty, SJ; Hernandez, I; Hinman, CR; Kang, AA; Karch, CM; Kaushik, S; Kosik, KS; Luna, G; Rauch, JN; Reis, SA; Sibih, YE; Storm, NJ; Zekanowski, C; Zhou, H | 1 |
| Adami, V; Anelli, V; Gatto, P; Mione, MC; Pancher, M; Precazzini, F; Tushe, A | 1 |
| Lempp, FA; Ni, Y; Urban, S | 1 |
| Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY | 1 |
| Groffen, J; Heisterkamp, N; Mishra, S; Zhang, B | 1 |
1 review(s) available for lonafarnib and Disease Models, Animal
| Article | Year |
|---|---|
Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.
Topics: Animals; Antiviral Agents; Cells, Cultured; Disease Models, Animal; Hepatitis D, Chronic; Hepatitis Delta Virus; Host-Pathogen Interactions; Humans; Interferon-alpha; Lipopeptides; Nucleic Acids; Piperidines; Pyridines; Virus Replication | 2016 |
7 other study(ies) available for lonafarnib and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
Topics: Aging; Animals; Bone and Bones; Bone Density Conservation Agents; Cartilage; Disease Models, Animal; Femur; Glycosaminoglycans; Joints; Lamin Type A; Mice; Mice, Transgenic; Mutation; Osteoarthritis; Phenotype; Piperidines; Pravastatin; Progeria; Protein Processing, Post-Translational; Pyridines; X-Ray Microtomography; Zoledronic Acid | 2020 |
Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
Topics: Adaptive Immunity; Animals; Disease Models, Animal; Drug Therapy, Combination; Genome, Viral; Glycoproteins; Hepatitis B virus; Hepatitis D; Hepatitis Delta Virus; Hepatocytes; Humans; Immunity, Innate; Immunocompetence; Lipopeptides; Mice, Inbred C57BL; Mice, Transgenic; Organic Anion Transporters, Sodium-Dependent; Piperidines; Pyridines; Symporters; Transgenes; Viremia | 2018 |
A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy.
Topics: Animals; Brain; Disease Models, Animal; Enzyme Inhibitors; Farnesyltranstransferase; Female; GTP-Binding Proteins; Humans; Induced Pluripotent Stem Cells; Lysosomes; Male; Mice; Mice, Transgenic; Mutation; Neurons; Piperidines; Proteolysis; Pyridines; RNA, Small Interfering; tau Proteins; Tauopathies; Translational Research, Biomedical | 2019 |
Automated in vivo screen in zebrafish identifies Clotrimazole as targeting a metabolic vulnerability in a melanoma model.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clotrimazole; Disease Models, Animal; Drug Screening Assays, Antitumor; Farnesyltranstransferase; Humans; Melanocytes; Melanoma; Melanoma, Cutaneous Malignant; Miconazole; Piperidines; Pyridines; Skin Neoplasms; Zebrafish | 2020 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Glioma; Humans; Mice; Neoplasm Transplantation; Piperidines; Prenylation; Pyridines; Radiation, Ionizing; ras Proteins; Signal Transduction; Temozolomide; Time Factors | 2011 |
A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Farnesyltranstransferase; Female; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Experimental; Lymphoma; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Nude; Mice, Transgenic; Piperazines; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Survival Rate; Tumor Cells, Cultured | 2004 |